Curry-Jones syndrome (CJS) is a multisystem disorder characterized by patchy skin lesions, polysyndactyly, diverse cerebral malformations, unicoronal craniosynostosis, iris colobomas, microphthalmia, and intestinal malrotation with myofibromas or hamartomas. Cerebellar medulloblastoma has been described in a single affected individual; in another, biopsy of skin lesions showed features of trichoblastoma. The combination of asymmetric clinical features, patchy skin manifestations, and neoplastic association previously led to the suggestion that this could be a mosaic condition, possibly involving hedgehog (Hh) signaling. Here, we show that CJS is caused by recurrent somatic mosaicism for a nonsynonymous variant in SMO (c.1234C>T [p.Leu412Phe]), encoding smoothened (SMO), a G-protein-coupled receptor that transduces Hh signaling. We identified eight mutation-positive individuals (two of whom had not been reported previously) with highly similar phenotypes and demonstrated varying amounts of the mutant allele in different tissues. We present detailed findings from brain MRI in three mutation-positive individuals. Somatic SMO mutations that result in constitutive activation have been described in several tumors, including medulloblastoma, ameloblastoma, and basal cell carcinoma. Strikingly, the most common of these mutations is the identical nonsynonymous variant encoding p.Leu412Phe. Furthermore, this substitution has been shown to activate SMO in the absence of Hh signaling, providing an explanation for tumor development in CJS. This raises therapeutic possibilities for using recently generated Hh-pathway inhibitors. In summary, our work uncovers the major genetic cause of CJS and illustrates strategies for gene discovery in the context of low-level tissue-specific somatic mosaicism.
The multiple-congenital-anomalies disorder Curry-Jones syndrome (MIM: 601707) was first presented (in abstract form) by Cynthia Curry and Marilyn Jones at the David W. Smith Workshop on Malformations and Morphogenesis in 1987. These authors described two unrelated individuals with the shared features of unilateral coronal craniosynostosis, cutaneous syndactyly, bilateral preaxial polydactyly of the feet, and unusual streaky skin lesions. Subsequently, the term Curry-Jones syndrome (CJS) was applied to this condition. 1, 2 The first formal publication on CJS was by Temple et al. 3 and included detailed clinical descriptions of the two original subjects and three further unrelated individuals. Four more simplex cases have since been added to the literature; each affected individual had abnormal skin patches and preaxial polydactyly of the feet. [4] [5] [6] Additional features found in most individuals have included ectopic hair growth, abnormalities of brain development, coloboma and/or microphthalmia, coronal suture synostosis, cutaneous syndactyly, and intestinal malrotation and/or obstruction (reviewed by Grange et al. 6 ). Figures 1A-1D show the major craniofacial, limb, and dermatological features of CJS in a previously unreported individual (subject 8 in our series); MRI scans of three individuals (Figures 1E-1G) illustrate the diversity of cerebral malformations (described in more detail below). Mild intellectual disability has been present in some individuals. In a single individual, a desmoplastic medulloblastoma (World Health Organization grade IV) of the right cerebellum, found incidentally on a follow-up brain MRI scan at 17 months, was treated successfully by surgical resection, chemotherapy, and radiotherapy. 6 In two individuals, biopsies of active skin lesions were reported to show features of either trichoblastoma 6 or nevus sebaceus. 3 In addition, odontogenic keratocysts have been found in one individual, and lesions in the bowel, identified histologically as hamartomas or myofibromas, were reported in three instances. 3, 6 The etiology of CJS was previously unknown, but three clinical observations are relevant to hypotheses for causation. First, the nine previously reported individuals comprised seven males and two females with similar disease severity, making an X-linked mutation unlikely. Second, the sporadic origin of all individuals in association with patchy skin lesions and asymmetric cranial findings led Temple et al. 3 to propose an underlying mosaic mutation; however, Grange et al. 6 favored a germline constitutional mutation in view of the consistent presentation and bilaterality of some of the other features. Third, the occurrence of medulloblastoma in basal cell nevus syndrome (BCNS [MIM: 109400])-caused by mutations in PTCH1 (MIM: 601309), which encodes the hedgehog (Hh) receptor-as well as the overlapping cranial and limb abnormalities found in disorders caused by mutations in GLI3 (MIM: 165240), a downstream effector of the Hh pathway, led Grange et al. 6 to propose that perturbation of Hh signaling could underlie CJS. However, sequencing of PTCH1 and GLI3 in DNA obtained from the blood of two individuals with CJS was normal. 6 The objective of the present work was to identify the causative mutation(s) underlying CJS through whole-exome sequencing (WES) by initially using an overlap strategy in four individuals to pinpoint disease-causing variants in the same gene. 3 these comprised both eyelid tissue (sample 1-2, collected during an operation to repair a malformed upper eyelid with ectopic hairs) and fibroblasts from an affected skin biopsy (sample 1-4) from subject 1 (the individual originally described by Jones) and fibroblasts from affected skin of subjects 2 (sample 2-3) and 3 (sample 3-2), the latter of whom was the individual originally described by Curry. All fibroblast lines were analyzed between three and five passages. An additional fifth sample (4-1) was from the blood of subject 4, an unpublished individual with features overlapping CJS. The clinical features of these four individuals are summarized in Table 1 (Table S1 ).
As an alternative approach, we compared the data from the two tissues separately sequenced from subject 1, given that mosaicism for a pathogenic variant could be detectable through differences in allele frequencies between datasets. Variants were ranked according to a somatic p value score generated by the software tool MiG, 9 which compares variant and reference read counts between two datasets ( Figure S1 ). The top hit was a nonsynonymous substitution in SMO (MIM: 601500; GenBank: NM_005631.4): c.1234C>T (p.Leu412Phe), present in 44 of 83 sequence reads from fibroblast sample 1-4. Notably, this variant was not called in the exome data from eyelid sample 1-2, although a low level of the same variant (2 of 40 sequence reads) was apparent on manual examination of the reads (Figure 2A ). The fortuitous presence of two heterozygous flanking SNPs (rs2228617 and rs2735842; dbSNP137) in this individual enabled the two SMO alleles to be easily distinguished. We noted that when sequence reads included both the c.1234 position and one of the flanking SNPs, the mutant c.1234T reads were always in cis with the variant allele of the SNP in both samples. However, for the eyelid sample 1-2, the converse was not true, supporting the conclusion that the c.1234C>T mutation was mosaic in this sample (see Figure 2) . SMO encodes smoothened (SMO), a frizzled G-protein-coupled receptor that plays a key role in transducing Hh signaling. Hh binding relieves patched-mediated suppression of SMO to allow transduction of the signal, probably mediated by conformational changes within the 7-transmembrane bundle.
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Hence, the variant matched all three criteria (autosomal, mosaic, and affecting Hh signaling) for the characteristics of a candidate CJS-associated gene on the basis of clinical deduction. 3, 6 Adding further weight to the conclusion sample 1-4 , the mutation appears to be present in the heterozygous state, and there is no evidence of dilution by non-mutant cells (red arrow). (Middle) In samples 1-2 and 2-3, a small proportion of the mutant c.1234T allele is suspected to be present on the basis of both the presence of a small T peak and the reduced relative height of the normal C peak (pink arrows; compare with the control at bottom). By contrast, the mutation does not appear to be present in samples 3-2 and 4-1.
that this was the pathogenic variant, the Catalogue of Somatic Mutations in Cancer (COSMIC) revealed that SMO c.1234C>T is a known mutation hotspot in multiple tumor types (discussed further below). Dideoxysequencing of SMO exon 6 in sample 1-4 confirmed the presence of the C>T variant in an apparently heterozygous state, but the mutant peak was barely visible in sample 1-2 ( Figure 2B ).
In light of this finding, we scrutinized the exome sequence data for SMO from the other three CJS individuals in greater detail. The identical c.1234C>T variant was present in 2.7% (6 of 219) of reads from sample 2-3 ( Figure S2 ) but was absent in the other two samples (0 of 57 reads from sample 3-2 and 0 of 179 reads from sample 4-1); no other suspicious SMO variant was detected in the exome sequences of subjects 3 or 4.
To gather further evidence that mosaic SMO mutations cause CJS, we collected and analyzed additional tissue samples from subjects 1-4 together with a further six individuals with CJS (subjects 5 and 6 reported by Grange et al., 6 subject 7 reported by Thomas et al., 5 and three unpublished individuals; clinical features are summarized in Table 1 ). Material from affected regions was prioritized and included archival formalin-fixed paraffin-embedded (FFPE) sections, such as those illustrated for affected skin and gut hamartoma in Grange et al. 6 (Table S2) . We used the Ion Torrent PGM to perform deep sequencing of SMO exon 6 in a total of 37 different tissue samples from the ten CJS subjects (including the previously sequenced samples) and three control samples. Table S3 lists the primer sequences and conditions used for SMO (GenBank: NG_023340.1) amplification and sequencing. Deep sequencing of DNA from subject 1 confirmed a~50% frequency for c.1234C>T in fibroblast sample 1-4 and showed that the variant was present at an 11% frequency in eyelid sample 1-2 ( Figure 3 and Table S2) . Surprisingly, we did not identify any mutant c.1234T alleles in the affected skin sample (1-3) from which the fibroblasts constituting sample 1-4 were derived, possibly indicating positive selection of mutant cells during growth in culture. In subject 2, the exome finding suggesting that the tested sample (2-3) was positive for an SMO mutation was validated, and c.1234C>T variant frequencies ranging from 4%-25% were detected in three of five samples, confirming mosaicism for the identical SMO mutation in this individual.
Deep sequencing of SMO in the samples used for exome sequencing (3-2 and 4-1) confirmed that the c.1234C>T mutation was essentially undetectable, given that the data were indistinguishable (by Fisher's exact test) from the control samples (Table S2 ). However, a new skin-biopsy sample from subject 3 was positive (14%), and a low level (1.6%) was detected in saliva. Furthermore, five of the six additional CJS individuals (subjects 5-8 and 10) were also mosaic for c.1234C>T (Figure 3 and Table S2 ). FFPE material from an occipital meningocele and cerebellar medulloblastoma were available from subject 5 (corresponding to patient 2 in Grange et al. 6 ), and analysis showed relatively high levels of mosaicism for the c.1234T allele at 20% and 43%, respectively. Similarly, the abdominal smooth muscle tumor sections from subject 6 (patient 1 in Grange et al.;
6 samples 6-3 and 6-4) contained the c.1234T allele at 35%-37%. In subject 7, a mildly affected individual, 5 we detected c.1234T at 3%-4% in skin (sample 7-1, taken from a hairy area of the inner leg) and associated fibroblasts (7-2), as well as a femoral bone marrow sample (7-5, 1%). Finally, we identified the c.1234T variant in samples from two unpublished individuals, subjects 8 ( Figures  1A-1D and 1G and Supplemental Note) and 10 ( Table 1) . FFPE samples from the colon (8-2) and cecum collected from subject 8 during investigation of intestinal malrotation and mesenteric masses (which contained hamartomatous nodules consisting of disorganized bundles of mature smooth muscle intermixed with nerve fibers and ganglion cells) contained the c.1234T allele at levels of 8%-9%. In subject 10, an affected skin sample and derived fibroblasts contained c.1234T at 33% and 16%, respectively ( Figure 3 ). In total, we identified the identical SMO c.1234C>T mutation in tissues from eight unrelated CJS-affected individuals, including the two originally described by Curry and Jones. In all but one sample (1-4, in which the mutation was originally identified by exome sequencing), the c.1234T allele was present at a level substantially below 50%, indicating tissue mosaicism. Importantly for diagnosis, we had the greatest success in detecting the mutation in affected tissues obtained by invasive procedures. The mutation was not reliably detected in blood samples from three mutation-positive individuals (levels of c.1234T ranged from 0.03% to 0.5%, which we believe is below the threshold for clinical diagnosis [1%]; Figure 3 and Table S2 ). We had greater success with saliva samples (mean ¼ 3.6% and range ¼ 0.11%-7.1% in four mutation-positive individuals), but in every individual, a Table S2. different tissue sample showed a higher mutation level (Figure 3 and Table S2 ). This suggests that the optimum strategy for detecting mosaic mutations in CJS is to sample affected skin and tissue from internal organs if available. In subjects 4 and 9, from whom only blood and saliva samples were available, levels of the c.1234C>T mutation were 0.11% or lower. Although the results for some samples differed from those of control samples on formal statistical testing, they were deemed indeterminate for clinical purposes. Deep sequencing of the entire SMO coding region did not identify any alternative variants (data not shown). Analysis of tissue samples from affected regions would be required for determining whether these two individuals in fact carry the canonical mutation or have a distinct genetic basis for their phenotype.
The finding of widespread mosaicism in CJS suggests that it arises post-zygotically early during embryonic development. A somewhat later acquisition of the mutation is predicted to cause isolated pathology of individual organs, so we explored this possibility in the context of the skin. We performed deep sequencing of SMO in 14 isolated trichoblastoma samples and a single nevus sebaceus sample, given that analysis of skin biopsies from subjects 1 and 6 had previously demonstrated nevus sebaceus 3 and trichoblastoma, 6 respectively. Although we detected rare SNPs, we did not find potentially pathological variants (Table S4) . We sought to further define the neuroanatomical features of CJS by reviewing recent MRI scans of three mutation-positive individuals (subjects 5, 6, and 8). A diverse range of phenotypes were present in this small sample; prominent features are illustrated in Figures 1E-1G , and the complete phenotype is summarized in Table S5 and presented in Figure S3 . Abnormal findings included hemimegalencephaly (HMEG) with cortical dysplasia, whitematter abnormalities and polymicrogyria, abnormalities of the corpus callosum, ventriculomegaly, occipital meningocele, and a Chiari type I malformation. Given the phenotypic overlap with isolated megalencephaly and/or HMEG and the previous observation of associated mutations in components of the PI3K-AKT pathway, [12] [13] [14] it would be of interest to test such mutation-negative brain samples for variants in SMO.
Although no constitutional mutations in SMO have previously been described, several hotspots of somatic mutation are evident in COSMIC, and it is striking that the most frequent of these is the identical c.1234C>T transition (note, this does not occur in the context of a CpG dinucleotide, so intrinsic hypermutability 15 is not predicted). Notably, the SMO c.1234C>T mutation has been identified in ameloblastoma, 16, 17 medulloblastoma, 18, 19 meningioma, 20, 21 and basal cell carcinoma (BCC); 22, 23 moreover, it has been reported as the oncogenic driver in some of these tumors. 16, 23 The altered amino acid Leu412 locates to transmembrane helix 5 of SMO within one of three pivot regions that, by analogy with the b 2 adrenergic receptor, 24 are likely to have a key role in the conformational changes required for receptor activation. Supporting this, the presence of mutant p.Leu412Phe leads to constitutive activation in the absence of Hh ligand in Smo À/À mouse embryonic fibroblasts 16, 22 and increased cell proliferation in ameloblast-lineage cells. 16 Vertebrates have three Hh ligands, sonic hedgehog (SHH), desert hedgehog (DHH), and Indian hedgehog (IHH), which remove inhibition of SMO by binding to the receptor patched (encoded by PTCH1 or PTCH2 [MIM: 603673]). Downstream effectors of Hh signal transduction, notably the transcription factors GLI2 and GLI3, are normally tethered by SUFU (suppressor of fused homolog) at the base of the primary cilium, where they are proteolytically processed to repressor forms (GLI2-R and GLI3-R, respectively). SMO activation leads to KIF7-dependent translocation toward the tip of the primary cilium and to transport of full-length activated GLI proteins (GLI2-A and GLI3-A) into the nucleus, enabling transcriptional activation (reviewed by Briscoe and Therond, 25 McCabe and Leahy, 26 and Arensdorf et al. 27 ). Activation of the PI3K-AKT-mTOR and/or PKA pathways can independently lead to GLI activation, indicating the potential for significant cross-talk with the Hh pathway. 28 (associated with BCNS), KIF7 (associated with acrocallosal syndrome), 35 and GLI3 (associated with Greig cephalopolysyndactyly). 36, 37 In addition, regulatory mutations in IHH (MIM: 600726) cause Philadelphia craniosynostosis. 38 Reflecting the net consequence of excessive Hh signal transduction, several clinical features of CJS overlap those of the above disorders, as previously noted. 6 These include craniosynostosis 39 in both Carpenter and Philadelphia craniosynostosis syndromes, preaxial polydactyly in Greig and Carpenter syndromes, 40 cerebral malformations in acrocallosal syndrome, 35 and odontogenic keratocysts and skin involvement in BCNS. 41 We also note overlap between the cerebral features and mosaic activation of components of the PI3K-AKT-mTOR pathway, such as in Proteus syndrome (MIM: 164730), fibroadipose hyperplasia and CLOVES syndrome (MIM: 612918), and HMEG (reviewed in Keppler-Noreuil et al., 12 Hevner, 13 and Jansen et al. 14 ). To our knowledge, abnormalities of the bowel have not previously been highlighted as a frequent feature of disorders associated with activation of Hh signaling, but they appear to be common in CJS (e.g., malrotation and myofibromas or hamartomas). These bowel abnormalities are consistent with the documented role of murine SHH and IHH, produced by the endodermal epithelium, as primary factors in the patterning and organogenesis of the gut, 42 where Hh signaling from the endoderm controls growth of the adjacent mesenchyme. 43 Mouse embryos in which Smo is deleted from the gut mesenchyme have severely reduced proliferation and differentiation of the intestinal mesenchyme and a reduced number of smooth muscle cells and enteric neurons. 44 Given the observed association between CJS and neoplastic diseases (trichoblastoma and cerebellar medulloblastoma), a particularly important consequence of identifying the activating p.Leu412Phe substitution in SMO concerns the potential pharmacotherapeutic implications for management of affected individuals. Recently, there has been considerable interest in developing SMO inhibitors to reduce activation of the Hh pathway (reviewed by Arensdorf et al. 27 ). For example, vismodegib is a clinically approved SMO inhibitor that contacts the extracellular domain and ligand-binding pocket. Interestingly, in a recent report of a subject with segmental BCNS associated with the identical SMO p.Leu412Phe substitution, 45 treatment with vismodegib for 4 months led to cessation of the appearance of new lesions and shrinkage of some existing BCCs. However, other reports have suggested that the p.Leu412Phe substitution confers resistance to vismodegib, supporting a role for Leu412 in autoinhibition and/or structural stability. 22, 23 This suggests that in CJS-associated tumors, the use of additional agents, such as arsenic trioxide or other more-specific GLI inhibitors or PI3K-AKT-mTOR inhibitors, that act at later stages of the Hh signal-transduction pathway should be explored, 33 and indeed there is evidence that this approach can be effective against p.Leu412Phe mutants. 16, 22 In summary, these data show that the major phenotypic features of CJS are attributable to excessive activation of Hh signaling owing to a specific c.1234C>T (p.Leu412Phe) somatic mutation. The finding that all eight mutation-positive individuals are mosaic might indicate that constitutional mutations are not compatible with life, as is true for several other sporadic autosomal disorders. 46 The mutation is likely to be associated with a spectrum of negative and positive selective consequences during organismal growth and homeostasis, depending on cell type, which most likely explains the apparent evolution of skin lesions and low mutation levels in blood (negative selection) and the predisposition to tumorigenesis (positive selection). The association between segmental BCNS and SMO p.Leu412Phe in a recent report 45 is compatible with a later occurrence of the somatic mutation during development than in subjects with the classical CJS phenotype.
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